BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CiviCRM//NONSGML CiviEvent iCal//EN
X-WR-TIMEZONE:Europe/London
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20261012T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:CiviCRM_EventID_2011_e86a4f28f24ec85011f2b11344e0bb4c@onenucleus.com
SUMMARY:Webinar - Working With China: Considerations for F
uture UK Biopharma Employment
X-ALT-DESC;FMTTYPE=text/html:There i
s no doubt about the rise of China as a major infl
uence in bio-innovation\, or indeed its plans to b
ecome increasingly competitive when you read their
recently published next five-year plan targeting
a goal key technological breakthroughs and aiming
for first-in-class new drugs to account for over 2
5 percent of the global total by 2030.
\n \n The impact on the UK Biopharma R&D landscap
e has been profound with Pharma\, investors and ou
tsourcing biotechs engaging with China to reduce t
imelines and cost in drug discovery. Whilst there
are perceived threats to China’s emergence\, many
will see opportunities for growth through collabor
ation\, strategically undertaking the respective p
arts of the R&D journey in the ecosystem best plac
ed to deliver them. Adapting to the new global bio
-innovation ecosystem which R&D roles will remain
in the UK sector and how UK employees can best pre
pare for them will be discussed in this webinar. <
br />\n
\n *Agenda:
\
n 16.00 Welcome and Introduction\,
\n David
Montgomery\, PM Life Sciences Consulting
\n 1
6.05 Why the UK should work with China
\n
Hazel Jones\, Laverock Therapeutics
\n 16.15
How can R&D scientists think laterally to progres
s their careers?
\n Natasha Robbins
\, Biotec Search
\n 16.25 Working in the Chi
na Life Sciences sector as an ex-pat
\n
Speaker tbc
\n 16.35 Open Q&D moderated
by David Montgomery
\n 16.55 Thanks from On
e Nucleus
\n 17.00 Close
\n *Subject to
change.
\n \n Registration
:
\n Free for all to attend but pre-registrat
ion essential.
DESCRIPTION:There is no doubt about the rise of China as a maj
or influence in bio-innovation\, or indeed its pla
ns to become increasingly competitive when you rea
d their recently published next five-year plan tar
geting a goal key technological breakthroughs and
aiming for first-in-class new drugs to account for
over 25 percent of the global total by 2030.\n \n
\n \n The impact on the UK Biopharma R&D landsca
pe has been profound with Pharma\, investors and o
utsourcing biotechs engaging with China to reduce
timelines and cost in drug discovery. Whilst there
are perceived threats to China’s emergence\, many
will see opportunities for growth through collabo
ration\, strategically undertaking the respective
parts of the R&D journey in the ecosystem best pla
ced to deliver them. Adapting to the new global bi
o-innovation ecosystem which R&D roles will remain
in the UK sector and how UK employees can best pr
epare for them will be discussed in this webinar.
\n \n \n \n *Agenda:\n \n 16.00 Welcome and Intr
oduction\,\n \n David Montgomery\, PM Life Science
s Consulting\n \n 16.05 Why the UK should work w
ith China \n \n Hazel Jones\, Laverock Therapeutic
s\n \n 16.15 How can R&D scientists think lateral
ly to progress their careers?\n \n Natas
ha Robbins\, Biotec Search\n \n 16.25 Working in
the China Life Sciences sector as an ex-pat\n \n
Speaker tbc\n \n 16.35 Open Q&D moderate
d by David Montgomery\n \n 16.55 Thanks from One
Nucleus\n \n 17.00 Close\n \n *Subject to change.
\n \n \n \n Registration:\n \n Free for all to att
end but pre-registration essential.\n \n
CATEGORIES:Events
CALSCALE:GREGORIAN
DTSTAMP;TZID=Europe/London:20261012T160000
DTSTART;TZID=Europe/London:20261012T160000
DTEND;TZID=Europe/London:20261012T170000
LOCATION:ONLINE - webinar details will be sent to all deleg
ates closer to the date of the event\n Cambridge\,
\n United Kingdom\n
URL:https://onenucleus.com/civicrm/event/info?reset=1&id=2011
END:VEVENT
END:VCALENDAR